SCHEMBL8947465

SCHEMBL8947465

Cc1ccc2c(/N=N/c3ccc(S(=O)(=O)O)cc3)c(O)ccc2c1

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.86
▸ CYP2C9 P11712 2/20 0.86
▸ THRB P10828 2/20 0.63
▸ MAPT P10636 3/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ MEN1 O00255 1/20 0.54
▸ MAPK1 P28482 2/20 0.54
▸ TDP1 Q9NUW8 2/20 0.54
▸ GAA P10253 1/20 0.54
▸ HIF1A Q16665 2/20 0.54
▸ TSHR P16473 1/20 0.54
▸ PTPRA P18433 1/20 0.54
▸ PTPRB P23467 1/20 0.54
▸ CYP2C19 P33261 1/20 0.54
▸ RAPGEF4 Q8WZA2 1/20 0.54
▸ HSD17B10 Q99714 1/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ RPS6KA3 P51812 1/20 0.51
▸ MPL P40238 3/20 0.48
▸ GLO1 Q04760 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1096315 0.92 CYP1A2 (1.00) CYP1A2CYP2C9THRBMAPTKMT2A
SCHEMBL1096317 0.92 CYP1A2 (1.00) CYP1A2CYP2C9THRBMAPTKMT2A
SCHEMBL15598887 0.92 CYP1A2 (1.00) CYP1A2CYP2C9THRBMAPTKMT2A
SCHEMBL27882609 0.91 CYP1A2 (0.97) CYP1A2CYP2C9THRBMAPTKMT2A
SCHEMBL112146 0.89 CYP1A2 (0.85) CYP1A2CYP2C9THRBMAPTKMT2A
SCHEMBL14418343 0.89 CYP1A2 (0.85) CYP1A2CYP2C9THRBMAPTKMT2A
SCHEMBL30940027 0.89 CYP1A2 (0.85) CYP1A2CYP2C9THRBMAPTKMT2A
SCHEMBL142459 0.89 CYP1A2 (0.85) CYP1A2CYP2C9THRBMAPTKMT2A
SCHEMBL628908 0.89 CYP1A2 (0.85) CYP1A2CYP2C9THRBMAPTKMT2A
SCHEMBL142457 0.88 CYP1A2 (0.83) CYP1A2CYP2C9THRBMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9504637-B2 Coloring agents and methods of use thereof LIVING PROOF, INC. (US) 2016-11-29 — — US disclosed
US-20160106648-A1 COLORING AGENTS AND METHODS OF USE THEREOF LIVING PROOF, INC. (US) 2016-04-21 — — US disclosed
US-9248086-B2 Coloring agents and methods of use thereof LIVING PROOF, INC. (US) 2016-02-02 — — US disclosed
US-20150174026-A1 COLORING AGENTS AND METHODS OF USE THEREOF LIVING PROOF, INC. 2015-06-25 — — US disclosed
US-8932370-B2 Coloring agents and methods of use thereof LIVING PROOF, INC. (US) 2015-01-13 — — US disclosed
US-20140326269-A1 COLORING AGENTS AND METHODS OF USE THEREOF LIVING PROOF, INC. 2014-11-06 — — US disclosed
US-8758451-B2 Coloring agents and methods of use thereof LIVING PROOF, INC. (US) 2014-06-24 — — US disclosed
US-20140013520-A1 COLORING AGENTS AND METHODS OF USE THEREOF LIVING PROOF, INC. 2014-01-16 — — US disclosed
US-8580143-B2 Lyotropic chromonic liquid crystal composition, method for manufacture of lyotropic chromonic liquid crystal coating film, and lyotropic chromonic liquid crystal coating film manufactured thereby KOREA INSTITUTE OF INDUSTRIAL TECHNOLOGY (KR) 2013-11-12 — — US disclosed
US-8444715-B2 Coloring agents and methods of use thereof LIVING PROOF, INC. (US) 2013-05-21 — — US disclosed
US-20120272990-A1 COLORING AGENTS AND METHODS OF USE THEREOF LIVING PROOF, INC. (US) 2012-11-01 — — US disclosed
US-8187340-B2 Coloring agents and methods of use thereof LIVING PROOF, INC. (US) 2012-05-29 — — US disclosed
US-20110272629-A1 LYOTROPIC CHROMONIC LIQUID CRYSTAL COMPOSITION, METHOD FOR MANUFACTURE OF LYOTROPIC CHROMONIC LIQUID CRYSTAL COATING FILM, AND LYOTROPIC CHROMONIC LIQUID CRYSTAL COATING FILM MANUFACTURED THEREBY INDUSTRIAL COOPERATION FOUNDATION CHONBUK NATIONAL UNIVERSITY (KR) 2011-11-10 — — US disclosed
US-20110154583-A1 COLORING AGENTS AND METHODS OF USE THEREOF LIVING PROOF, INC. (US) 2011-06-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120272990-A1 COLORING AGENTS AND METHODS OF USE THEREOF MPO, HLA-C, ADH7 CYP1A2 1159/4885CYP2C9 1172/4885THRB 4668/4885
US-20110154583-A1 COLORING AGENTS AND METHODS OF USE THEREOF MPO, HLA-C, ADH7 CYP1A2 1159/4885CYP2C9 1172/4885THRB 4668/4885
US-20160106648-A1 COLORING AGENTS AND METHODS OF USE THEREOF MPO, HLA-C, ADH7 CYP1A2 1159/4885CYP2C9 1172/4885THRB 4668/4885
US-20140013520-A1 COLORING AGENTS AND METHODS OF USE THEREOF MPO, HLA-C, ADH7 CYP1A2 1159/4885CYP2C9 1172/4885THRB 4668/4885
US-20150174026-A1 COLORING AGENTS AND METHODS OF USE THEREOF MPO, HLA-C, ADH7 CYP1A2 1159/4885CYP2C9 1172/4885THRB 4668/4885
US-20140326269-A1 COLORING AGENTS AND METHODS OF USE THEREOF MPO, HLA-C, ADH7 CYP1A2 1159/4885CYP2C9 1172/4885THRB 4668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback